Literature DB >> 18418400

The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with beta-blockade.

A Kelley-Hedgepeth, I Peter, Ke Kip, Mc Montefusco, S Kogan, D Cox, Jm Ordovas, D Levy, Se Reis, Me Mendelsohn, D Housman, Gs Huggins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18418400      PMCID： PMC2659689          DOI： 10.1038/jhh.2008.23

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN： 0950-9240            Impact factor:   3.012


× No keyword cloud information.
  12 in total

1.  Association analysis between hypertension and CYBA, CLCNKB, and KCNMB1 functional polymorphisms in the Japanese population--the Suita Study.

Authors:  Yoshihiro Kokubo; Naoharu Iwai; Naomi Tago; Nozomu Inamoto; Akira Okayama; Hideyuki Yamawaki; Hiroaki Naraba; Hitonobu Tomoike
Journal:  Circ J       Date:  2005-02       Impact factor: 2.993

2.  Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure.

Authors:  Martin D Tobin; Nuala A Sheehan; Katrina J Scurrah; Paul R Burton
Journal:  Stat Med       Date:  2005-10-15       Impact factor: 2.373

3.  Protective effect of the KCNMB1 E65K genetic polymorphism against diastolic hypertension in aging women and its relevance to cardiovascular risk.

Authors:  Mariano Sentí; José M Fernández-Fernández; Marta Tomás; Esther Vázquez; Roberto Elosua; Jaume Marrugat; Miguel A Valverde
Journal:  Circ Res       Date:  2005-11-17       Impact factor: 17.367

4.  Regulation of arterial diameter and wall [Ca2+] in cerebral arteries of rat by membrane potential and intravascular pressure.

Authors:  H J Knot; M T Nelson
Journal:  J Physiol       Date:  1998-04-01       Impact factor: 5.182

5.  Vasoregulation by the beta1 subunit of the calcium-activated potassium channel.

Authors:  R Brenner; G J Peréz; A D Bonev; D M Eckman; J C Kosek; S W Wiler; A J Patterson; M T Nelson; R W Aldrich
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

6.  Downregulation of the BK channel beta1 subunit in genetic hypertension.

Authors:  Gregory C Amberg; L Fernando Santana
Journal:  Circ Res       Date:  2003-10-09       Impact factor: 17.367

7.  Assembly of a Ca2+-dependent BK channel signaling complex by binding to beta2 adrenergic receptor.

Authors:  Guoxia Liu; Jingyi Shi; Lin Yang; Luxiang Cao; Soo Mi Park; Jianmin Cui; Steven O Marx
Journal:  EMBO J       Date:  2004-05-13       Impact factor: 11.598

8.  Gain-of-function mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension.

Authors:  José M Fernández-Fernández; Marta Tomás; Esther Vázquez; Patricio Orio; Ramón Latorre; Mariano Sentí; Jaume Marrugat; Miguel A Valverde
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

9.  KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).

Authors:  Amber L Beitelshees; Yan Gong; Danxin Wang; Nicholas J Schork; Rhonda M Cooper-Dehoff; Taimour Y Langaee; Mark D Shriver; Wolfgang Sadee; Harm J Knot; Carl J Pepine; Julie A Johnson
Journal:  Pharmacogenet Genomics       Date:  2007-09       Impact factor: 2.089

10.  Modulation of the molecular composition of large conductance, Ca(2+) activated K(+) channels in vascular smooth muscle during hypertension.

Authors:  Gregory C Amberg; Adrian D Bonev; Charles F Rossow; Mark T Nelson; Luis F Santana
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808
View more
  11 in total

Review 1.  BK channels and a new form of hypertension.

Authors:  P Richard Grimm; Steven C Sansom
Journal:  Kidney Int       Date:  2010-08-18       Impact factor: 10.612

2.  Pharmacogenomics of antihypertensive drugs: past, present and future.

Authors:  Julie A Johnson
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

Review 3.  Role of BK channels in hypertension and potassium secretion.

Authors:  J David Holtzclaw; P Richard Grimm; Steven C Sansom
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-09       Impact factor: 2.894

4.  Smooth muscle BK channel activity influences blood pressure independent of vascular tone in mice.

Authors:  Gregor Sachse; Jörg Faulhaber; Anika Seniuk; Heimo Ehmke; Olaf Pongs
Journal:  J Physiol       Date:  2014-03-31       Impact factor: 5.182

Review 5.  Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance.

Authors:  Donna K Arnett; Steven A Claas
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

6.  The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs.

Authors:  Jean-Philippe Fortin; Lei Ci; Jonathan Schroeder; Carmit Goldstein; Maria Claudia Montefusco; Inga Peter; Steven E Reis; Gordon S Huggins; Martin Beinborn; Alan S Kopin
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

7.  The KCNMB1 E65K variant is associated with reduced central pulse pressure in the community-based Framingham Offspring Cohort.

Authors:  Alyson Kelley-Hedgepeth; Inga Peter; Maria Claudia Montefusco; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan; Michael E Mendelsohn; David Housman; Gordon S Huggins; Gary F Mitchell
Journal:  J Hypertens       Date:  2009-01       Impact factor: 4.844

8.  Little ROCK is a ROCK1 pseudogene expressed in human smooth muscle cells.

Authors:  Maria Claudia Montefusco; Kristen Merlo; Crystal D Bryan; Howard K Surks; Steven E Reis; Michael E Mendelsohn; Gordon S Huggins
Journal:  BMC Genet       Date:  2010-04-14       Impact factor: 2.797

Review 9.  Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension?

Authors:  Donna K Arnett; Steven A Claas; Amy I Lynch
Journal:  Curr Opin Cardiol       Date:  2009-07       Impact factor: 2.161

Review 10.  Single-nucleotide polymorphisms in vascular Ca2+-activated K+-channel genes and cardiovascular disease.

Authors:  Ralf Köhler
Journal:  Pflugers Arch       Date:  2009-12-31       Impact factor: 3.657
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.